Conditions: HIV HIV Infections
Keywords: Treatment Experienced
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 79
Healthy volunteers: no

Brief summary:
The purpose of this study is to provide open-label vicriviroc (VCV) to human immunodeficiency virus (HIV) treatment-experienced participants who successfully completed 48 weeks of treatment on Acquired Immunodeficiency Syndrome (AIDS) Clinical Trial Group (ACTG) protocol A5211 (or who responded favorably to treatment but discontinued participation due to viral tropism shifts), and participants who screened for ACTG A5211 and met all inclusion/exclusion criteria, but were unable to enroll due to protocol closure.

Detailed description:

Arms:
arm 1: Participants take VCV 30 mg once daily.

Interventions: intervention 1: Vicriviroc maleate
Intervention descriptions: intervention 1: VCV 30 mg tablet once daily by mouth.

Protocol document: